ReviewChest2013
Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Review in Chest, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02664792 (Use of [18]F-FDG - PET/CT in Brazil Unified Health System), which is not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of [18]F-FDG - PET/CT in Brazil Unified Health System (SUS) as an Alternative Non-invasive Method for Staging of Lung Cancer
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 250 citations in OpenAlex.
- Guideline
- Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.International journal of oncology · 2015Trial
- Predicting 5-Year Mortality in Non-Small-Cell Lung Cancer Using the Korean Central Cancer Registry: Model Development and Validation Study.JMIR medical informatics · 2026Article
- The Impact of Artificial Intelligence on Lung Cancer Diagnosis and Personalized Treatment.International journal of molecular sciences · 2025Review
- Perioperative Therapy in Oncogene-Driven Non-Small Cell Lung Cancer: Current Strategies and Unanswered Questions.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2025Review
- NSCLC: Current Evidence on Its Pathogenesis, Integrated Treatment, and Future Perspectives.Journal of clinical medicine · 2025Review
- One-step diagnosis of infection and lung cancer using metagenomic sequencing.Respiratory research · 2025Article
- Mathematical modeling in the health risk assessment of air pollution-related disease burden in China: A review.Frontiers in public health · 2022Review
- The Epidemiology of Lung Metastases.Frontiers in medicine · 2021Article
- Knockdown of ubiquitin‑specific protease 51 attenuates cisplatin resistance in lung cancer through ubiquitination of zinc‑finger E‑box binding homeobox 1.Molecular medicine reports · 2020Article
- The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.Carcinogenesis · 2020Article
- EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.BMC pulmonary medicine · 2019Article
- Identification of key biomarkers and potential molecular mechanisms in lung cancer by bioinformatics analysis.Oncology letters · 2019Article
- SHCBP1 regulates apoptosis in lung cancer cells through phosphatase and tensin homolog.Oncology letters · 2019Article
- Liquid Biopsy in Solid Malignancy.Genetic testing and molecular biomarkers · 2019Review
- Discovery of pre-therapy 2-deoxy-2-European journal of nuclear medicine and molecular imaging · 2019Article
- miR-339-5p inhibits lung adenocarcinoma invasion and migration by directly targeting BCL6.Oncology letters · 2018Article
- Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer.Thoracic cancer · 2018Article
- Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer.Cancer science · 2017Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Based on recent bench and clinical research, the treatment of lung cancer has been refined, with treatments allocated according to histology and specific molecular features. For example, targeting mutations such as epidermal growth factor receptor (EGFR) with tyrosine kinase inhibitors has been particularly successful as a treatment modality, demonstrating response rates in selected patients with adenocarcinoma tumors harboring EGFR mutations that are significantly higher than those for conventional chemotherapy. However, the development of new targeted therapies is, in part, highly dependent on an improved understanding of the molecular underpinnings of tumor initiation and progression, knowledge of the role of molecular aberrations in disease progression, and the development of highly reproducible platforms for high-throughput biomarker discovery and testing. In this article, we review clinically relevant research directed toward understanding the biology of lung cancer. The clinical purposes of this research are (1) to identify susceptibility variants and field molecular alterations that will promote the early detection of tumors and (2) to identify tumor molecular alterations that serve as therapeutic targets, prognostic biomarkers, or predictors of tumor response. We focus on research developments in the understanding of lung cancer somatic DNA mutations, chromosomal aberrations, epigenetics, and the tumor microenvironment, and how they can advance diagnostics and therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.